Alessandro Granito
Università degli Studi di Bologna
H-index: 64
Europe-Italy
Top articles of Alessandro Granito
Aetiology of hepatocellular carcinoma and response to immunotherapy: is the problem inherent in the classification of non-viral disease?
Digestive and Liver Disease
2024/2/1
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy
Current Oncology
2024/1/19
Fabio Conti
H-Index: 6
Franco Trevisani
H-Index: 42
Alessandro Granito
H-Index: 34
Francesco Tovoli
H-Index: 23
Autoimmune Polyendocrine Syndromes in Adult Italian Celiac Disease Patients
Journal of Clinical Medicine
2024/1/16
From an understanding of etiopathogenesis to novel therapies—what is new in the treatment of celiac disease?
2024/4/18
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib
Internal and Emergency Medicine
2024/3/29
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib
Cancers
2024/3/7
Alessandro Granito
H-Index: 34
Paolo Caraceni
H-Index: 39
Annagiulia Gramenzi
H-Index: 20
Franco Trevisani
H-Index: 42
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care
Digestive and Liver Disease
2024/2/9
Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: data from a multicenter collaborative study
Digestive and Liver Disease
2024/2/1
Management of portal hypertension in patients receiving atezolizumab-bevacizumab for hepatocellular carcinoma
Digestive and Liver Disease
2024/2/1
Comparative analysis of subclassification models in patients with intermediate stage hepatocellular carcinoma (BCLC B) receiving systemic therapy
Digestive and Liver Disease
2024/2/1
Prognostic impact of previous intraarterial treatment in patients with hcc treated with sorafenib
Digestive and Liver Disease
2023/3/1
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis
Current Oncology
2023/2/22
A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination …
Gastroenterology Insights
2023/2/12
Alessandro Granito
H-Index: 34
Francesco Tovoli
H-Index: 23
Paraneoplastic anti-Tif1-gamma autoantibody-positive dermatomyositis as clinical presentation of hepatocellular carcinoma recurrence
Journal of Clinical and Translational Hepatology
2023/2/2
Alessandro Granito
H-Index: 34
Predictors of non‐transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection
Liver International
2023/12
Filippo Pelizzaro
H-Index: 1
Franco Trevisani
H-Index: 42
Umberto Cillo
H-Index: 44
Gianpaolo Vidili
H-Index: 15
Maria Guarino
H-Index: 22
Gerardo Nardone
H-Index: 35
Fabio Farinati
H-Index: 40
Paolo Caraceni
H-Index: 39
Alessandro Granito
H-Index: 34
Francesco Tovoli
H-Index: 23
Federico Ravaioli
H-Index: 14
Andrea Pasta
H-Index: 3
Paolo Giuffrida
H-Index: 1
Andrea Casadei Gardini
H-Index: 24
Fabio Conti
H-Index: 6
Giorgio Ercolani
H-Index: 43
Filomena Morisco
H-Index: 31
Mario Capasso
H-Index: 26
Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
Life
2023/11/6
Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.
2023/2/1
Clinical impact of relative dose intensity of cabozantinib during the first 8 weeks and of subsequent dose reductions in patients with unresectable hepatocellular carcinoma
Digestive and Liver Disease
2023/9/1
Sequential systemic treatments for hepatocellular carcinoma: real-life clinical practice data in the time of multiple agents
Digestive and Liver Disease
2023/9/1
COVID-19: has the liver been spared?
2023/1/6
Alessandro Granito
H-Index: 34
Francesco Tovoli
H-Index: 23
Co-Authors
